What You Ought to Know:
– Promise Bio, a startup remodeling immune-mediated illness therapy with superior precision drugs options, at this time introduced its emergence from stealth with an $8.3 million seed funding.
– This funding will speed up the event of Promise Bio’s computational platform, which makes use of epiproteomics and synthetic intelligence to foretell affected person therapy responses and assist drug analysis and improvement.
Revolutionizing Immune-Mediated Illness Administration by way of Epiproteomics and AI
Promise Bio is a trailblazer in precision drugs, advancing the administration of immune-mediated ailments with an progressive deal with epiproteomics and synthetic intelligence (AI). Leveraging groundbreaking analysis from the Weizmann Institute of Science, the corporate’s proprietary know-how allows large-scale profiling of post-translational modifications (PTMs) in proteins. This platform identifies illness mechanisms, customizes therapies, and uncovers novel drug targets with unparalleled precision.
On the core of Promise Bio’s success is its proprietary PROMISE (Protein Modification Built-in Search Engine) platform, developed by Co-Founder & CTO Dr. Assaf Kacen. This cutting-edge system, based mostly on foundational analysis performed in Prof. Yifat Merbl’s lab on the Weizmann Institute and printed in Nature Biotechnology in 2023, permits high-throughput profiling of dozens of PTMs utilizing mass spectrometry. The platform eliminates the necessity for custom-made chemical enrichment or extra lab procedures, considerably streamlining the evaluation of PTMs and accelerating biomedical discovery.
Strategic partnerships with two main biopharmaceutical corporations improve Promise Bio’s capability to combine its know-how into world drug improvement pipelines. These alliances present:
- Monetary assist, guaranteeing sustained innovation.
- Business experience, enabling efficient translation of analysis into medical functions.
- Entry to world networks, fostering collaboration and increasing the attain of precision drugs options.
By constructing the world’s largest PTM database, Promise Bio is creating an indispensable useful resource for medical breakthroughs whereas addressing urgent medical challenges in immune-mediated ailments.
Addressing the unmet want for precision remedies, Promise Bio targets the present inefficiencies in autoimmune illness therapies, the place solely 30–40% of sufferers obtain important remission. The corporate emphasizes data-driven approaches to eradicate the trial-and-error therapy paradigm. Its PROMISE platform focuses not solely on protein ranges but additionally on the modifications proteins bear after formation, delivering actionable insights for tailor-made interventions.
“Proteins are the constructing blocks of the human physique, and understanding their post-formation adjustments is vital to fixing the challenges in immune-mediated ailments,” defined Ronel Veksler, Co-Founder & CEO. With this imaginative and prescient, Promise Bio is poised to rework the way forward for precision drugs.
